Acro Biomedical Co., Ltd.
ACBM
$0.0007
-$0.1043-99.33%
OTC PK
| 03/31/2025 | 09/30/2024 | 03/31/2024 | 12/31/2023 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | -57.42% | -32.59% | -32.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -70.57% | -46.80% | -46.80% |
| Operating Income | -- | -- | 69.90% | 44.60% | 44.60% |
| Income Before Tax | -- | -- | 69.81% | 44.51% | 44.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | 69.81% | 44.51% | 44.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 69.81% | 44.51% | 44.51% |
| EBIT | -- | -- | 69.90% | 44.60% | 44.60% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | 69.80% | 44.49% | 44.49% |
| Normalized Basic EPS | -- | -- | 69.90% | 44.59% | 44.59% |
| EPS Diluted | -- | -- | 69.80% | 44.49% | 44.49% |
| Normalized Diluted EPS | -- | -- | 69.90% | 44.59% | 44.59% |
| Average Basic Shares Outstanding | -- | -- | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | -- | -- | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |